Scholar Rock Holding Corporation (SRRK)
Nasdaq: SRRK · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Who owns Scholar Rock Holding Corporation
As filed with the SECHolders of 5% or more
5
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 12, 2025 says.
Directors and officers
15
report now, of 28 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 12, 2025 · COMMON STOCK
Invus Public Equities, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.001 per share · 11.4% in Feb 12, 2025
Srinivas Akkaraju
SCHEDULE 13D/A · filed Oct 7, 2025 · Common Stock, par value $0.001 per share
Wellington Management Group LLP
SCHEDULE 13G · filed Feb 10, 2026 · Common Stock
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · 7.2% in Nov 14, 2025
Redmile Group, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.6% in May 15, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What SRRK reports owning in othersstakes of 5% or more, and other ties
8 subsidiaries in 5 countries, from the list filed with the 10-K filed Mar 3, 2026.
Insider tradesForm 4
38sales
6purchases
22sales on a scheduled plan
13people selling
$19.4Msold, in dollars
$12.0Mbought, in dollars
Open-market trades on Form 4 from Oct 27, 2025 to Oct 27, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 27, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window14 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 9 | $8.6M | 7 | 0 | $0 |
| Hallal David | Chief Executive Officer | 2 | $4.0M | 0 | 0 | $0 |
| Vaishnaw Akshay | President of R&D | 2 | $1.5M | 0 | 0 | $0 |
| Sinha Vikas | Chief Financial Officer | 2 | $1.2M | 0 | 0 | $0 |
| Woods Keith | Chief Operating Officer | 2 | $1.2M | 0 | 0 | $0 |
| Ho Junlin | GENERAL COUNSEL | 2 | $800,000 | 0 | 0 | $0 |
| Parlavecchio Caryn | CHRO | 2 | $700,000 | 0 | 0 | $0 |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 2 | $500,000 | 0 | 0 | $0 |
| Peng Katie | director | 5 | $300,000 | 5 | 0 | $0 |
| Burow Kristina | director | 2 | $200,000 | 2 | 0 | $0 |
| Flier Jeffrey S. | director | 3 | $200,000 | 3 | 0 | $0 |
| Reed Joshua | director | 2 | $200,000 | 2 | 0 | $0 |
| Gilman Michael | director | 3 | $100,000 | 3 | 0 | $0 |
| Akkaraju Srinivas | director | 0 | $0 | 0 | 6 | $12.0M |